The main purpose of this legislation is to restrict certain healthcare funding for transgender-related medical services. Specifically, it aims to prevent entities that participate in the 340B Drug Pricing Program from using savings generated through this program to cover costs associated with sex reassignment surgeries and hormone therapies for transgender individuals. Key provisions of the legislation include a clear prohibition on the use of funds derived from the 340B program for specific services related to gender alteration.